



## Commercial Preauthorization and Notification List

Effective date: Jan. 1, 2024

Revision date: Jan. 8, 2025

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Abecma intravenous suspension <sup>‡</sup>	idecabtagene vicleucel <sup>‡</sup>	Q2055
Abraxane <sup>‡,††</sup>	nab-paclitaxel <sup>‡,††</sup>	J9264
Actemra IV <sup>††</sup>	tocilizumab <sup>††</sup>	J3262
Adakveo <sup>‡</sup>	crizanlizumab-tmca <sup>‡</sup>	J0791
Adcetris	brentuximab vedotin	J9042
Adstiladrin	nadofaragene firadenovec-vncg	J9029
Aduhelm	aducanumab-avwa	J0172
Adzynma	ADAMTS13, recombinant-krhn	J7171
Akynzeo IV	fosnetupitant and palonosetron	J1454
Aldurazyme	laronidase	J1931
Alimta	pemetrexed	J9305
Aliqopa	copanlisib	J9057
Aloxi <sup>††</sup>	palonosetron <sup>††</sup>	J2469
Alyglo <sup>*, †, ‡, ††</sup>	immune globulin intravenous, human-stwk <sup>*, †, ‡, ††</sup>	C9399, J1599
Alymsys <sup>‡, ††</sup>	bevacizumab-maly <sup>‡, ††</sup>	Q5126
Amondys-45	casimersen	J1448
Amtagvi <sup>*, †, ‡, ††</sup>	lifileucel <sup>*, †, ‡, ††</sup>	C9399, J3490, J9999
Amvuttra <sup>‡</sup>	vutrisiran <sup>‡</sup>	J0225
Anktiva <sup>*, †, ‡</sup>	nogapendekin alfa inbakicept-pmln <sup>*, †, ‡</sup>	C9169, J3490, J3590, J9999
Aphexda	motixafortide	J2277
Aralast NP <sup>‡</sup>	alpha 1-proteinase inhibitor <sup>‡</sup>	J0256
Aranesp <sup>††</sup>	darbepoetin alfa <sup>††</sup>	J0881, J0882

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Arcalyst	rilonacept	J2793
Asceniv <sup>††</sup>	immune globulin <sup>††</sup>	J1554
Asparlas	calaspargase pegol-mknl	J9118
Aucatzyl <sup>*,†,‡,‡‡</sup>	obecabtagene autoleucel <sup>*,†,‡,‡‡</sup>	C9399, J3490, J9999
Avastin ( <i>authorization required only for oncology/chemotherapy use</i> ) <sup>*</sup>	bevacizumab (oncology only) <sup>*</sup>	C9257, J9035
Aveed <sup>††</sup>	testosterone undecanoate <sup>††</sup>	J3145
Avsola <sup>‡,††</sup>	infliximab-axxq <sup>‡,††</sup>	Q5121
Axtle <sup>*,†,‡</sup>	pemetrexed <sup>*,†,‡</sup>	C9399, J3490, J9999
Azedra	iobenguane I 131	A9590, C9407, C9408
Bavencio	avelumab	J9023
Beleodaq	belinostat	J9032
Belrapzo <sup>‡</sup>	bendamustine hydrochloride <sup>‡</sup>	J9036
bendamustine <sup>‡</sup>	bendamustine hydrochloride <sup>‡</sup>	J9036
bendamustine (Apotex)	bendamustine hydrochloride	J9058
bendamustine (Baxter)	bendamustine hydrochloride	J9059
Bendeka	bendamustine hydrochloride	J9034
Benlysta	belimumab	C9399, J0490, J3590
Beovu <sup>††</sup>	brolocizumab-dbl <sup>††</sup>	J0179
Beriner <sup>††</sup>	C1 esterase inhibitor (human) <sup>††</sup>	J0597
Besponsa	inotuzumab ozogamicin	J9229
Bivigam <sup>††</sup>	immune globulin <sup>††</sup>	J1556
Bizengri <sup>*,†,‡</sup>	zenocutuzumab-zbco <sup>*,†,‡</sup>	C9399, J3490, J3590, J9999
Blenrep <sup>‡</sup>	belantamab mafodotin-blmf <sup>‡</sup>	J9037
Blinicyto	blinatumomab	J9039
<b>Blood-clotting factors (see list on pages 15–16)</b>		
bortezomib <sup>‡</sup>	bortezomib <sup>‡</sup>	J9041
bortezomib (Dr. Reddy's)	bortezomib	J9046

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
bortezomib (Fresenius Kabi)	bortezomib	J9048
bortezomib (Hospira)	bortezomib	J9049
bortezomib (Maia)	bortezomib	J9051
Boruzu <sup>*,†,‡</sup>	bortezomib <sup>*,†,‡</sup>	C9399, J3490, J9999
Botox	onabotulinumtoxinA	J0585
Breyanzi <sup>‡‡</sup>	lisocabtagene maraleucel <sup>‡‡</sup>	Q2054
Brineura	cerliponase alfa	J0567
Briumvi <sup>†</sup>	ublituximab-xiiy <sup>†</sup>	J2329
Byooviz <sup>††</sup>	ranibizumab-nuna intravitreal solution <sup>††</sup>	Q5124
cabazitaxel (Sandoz)	cabazitaxel	J9064
Carvykti <sup>‡‡</sup>	ciltacabtagene autoleucel <sup>‡‡</sup>	Q2056
Casgev <sup>*,†,‡,††</sup>	exagamglogene autotemcel <sup>*,†,‡,††</sup>	C9399, J3490
Cerezyme	imiglucerase	J1786
Cimerli <sup>††</sup>	ranibizumab-eqrn <sup>††</sup>	Q5128
Cimzia	certolizumab pegol	J0717
Cinqair	reslizumab	J2786
Cinryze <sup>††</sup>	C1 esterase inhibitor (human) <sup>††</sup>	J0598
Cinvanti	aprepitant	C9145, J0185
Cortrophin Gel	adrenocorticotrophic hormone (ACTH)	J0802
Cosela	trilaciclib	J1448
Columvi <sup>*,†</sup>	glofitamab-gxbm <sup>*,†</sup>	J9286
Cosentyx IV <sup>††</sup>	secukinumab <sup>††</sup>	J3247
Crysvita	burosumab-twza	J0584
Cutaquig <sup>††</sup>	immune globulin <sup>††</sup>	J1551
Cuvitru <sup>††</sup>	immune globulin <sup>††</sup>	J1555
Cyklokapron <sup>‡</sup>	tranexamic acid <sup>‡</sup>	J3490
Cyramza	ramucirumab	J9308
Danyelza	naxitamab-ggqk	J9348
Darzalex	daratumumab	J9145
Darzalex Faspro <sup>‡</sup>	daratumumab and hyaluronidase-fihj <sup>‡</sup>	J9144
Daxxify	daxibotulinumtoxinA-lann	J0589

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Defitelio <sup>‡</sup>	defibrotide sodium <sup>‡</sup>	C9399, J3490
Docivyx <sup>*,†,‡</sup>	docetaxel <sup>*,†,‡</sup>	C9399, J3490, J9999
Doxil <sup>††</sup>	doxorubicin HCL liposome injection <sup>††</sup>	Q2050
Duopa <sup>††</sup>	carbidopa/levodopa <sup>††</sup>	J7340
Dupilixent <sup>‡,††</sup>	dupilumab <sup>‡,††</sup>	C9399, J3590
Durolane <sup>††</sup>	hyaluronic acid, stabilized <sup>††</sup>	J7318
Durysta <sup>‡</sup>	bimatoprost implant <sup>‡</sup>	J7351
Dysport <sup>††</sup>	abobotulinumtoxin A <sup>††</sup>	J0586
Elahere <sup>*,†</sup>	mirvetuximab soravtansine-gynx <sup>*,†</sup>	J9063
Elaprase	idursulfase	J1743
Elelyso	taliglucerase alfa	J3060
Elevidys <sup>*,†</sup>	delandistrogene moxeparvovec-rokl <sup>*,†</sup>	J1413
Elfabrio IV <sup>*,†</sup>	pegunigalsidase alfa-iwxj <sup>*,†</sup>	J2508
Elitek	rasburicase	J2783
Elrexfio	elranatamab-bcmm	J0177
Elzonris	tagraxofusp-erzs	J9269
Empaveli <sup>‡</sup>	pegcetacoplan <sup>‡</sup>	C9399, J3490
Empliciti	elotuzumab	J9176
Enhertu	fam-trastuzumab deruxtecan-nxki	J9358
Enjaymo	sutimlimab-jome	J1302
Enspryng <sup>‡</sup>	satralizumab-mwge <sup>‡</sup>	C9399, J3490, J3590
Entyvio IV <sup>††</sup>	vedolizumab <sup>††</sup>	J3380
Epkinly	epcoritamab-bysp	J9321
Epogen <sup>‡,††</sup>	epoetin alfa <sup>‡,††</sup>	J0885, Q4081
Erbitux	cetuximab	J9055
Erwinase <sup>‡</sup>	crisantaspase <sup>‡</sup>	J9019
Erwinaze <sup>‡</sup>	asparaginase erwinia chrysanthemi <sup>‡</sup>	J9019
Eskata <sup>‡</sup>	hydrogen peroxide <sup>‡</sup>	C9399, J3490
Evkeeza <sup>††</sup>	evinacumab-dgnb <sup>††</sup>	J1305
Euflexxa <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7323
Evenity	romosozumab-aqqg	J3111

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Exondys 51	eteplirsen	J1428
Eylea <sup>††</sup>	aflibercept <sup>††</sup>	J0178
Eylea HD	aflibercept	J0177
Fabrazyme	agalsidase beta	J0180
Fasenra	benralizumab	J0517
Faslodex	fulvestrant	J9395
Feraheme <sup>††</sup>	ferumoxylol <sup>††</sup>	Q0138
Firazyr <sup>‡,††</sup>	icatibant <sup>‡,††</sup>	J1744
Flebogamma <sup>‡</sup>	immune globulin <sup>‡</sup>	J1572
Flebogamma DIF <sup>‡</sup>	immune globulin <sup>‡</sup>	J1572
Flolan <sup>‡,††</sup>	epoprostenol (injection) <sup>‡,††</sup>	J1325, J3490, S0155
Folotyn <sup>‡</sup>	pralatrexate <sup>‡</sup>	J9307
Fulphila	pegfilgrastim-jmdb	Q5108
fulvestrant (Fresenius Kabi)	fulvestrant	J9394
fulvestrant (Teva)	fulvestrant	J9393
Fusilev <sup>‡,††</sup>	levoleucovorin calcium <sup>‡,††</sup>	J0641
Fyarro	sirolimus protein-bound particles for injectable suspension	J9331
Fylnetra <sup>‡,†,††</sup>	pegfilgrastim-pbbk <sup>‡,†,††</sup>	Q5130
GamaSTAN <sup>‡</sup>	immune globulin <sup>‡</sup>	J1460, J1560
GamaSTAN S/D <sup>‡</sup>	immune globulin <sup>‡</sup>	J1460, J1560
Gamifant <sup>††</sup>	emapalumab-lzsg <sup>††</sup>	J9210
Gammagard	immune globulin	J1569
Gammagard S/D	immune globulin	J1566
Gammaked <sup>‡</sup>	immune globulin <sup>‡</sup>	J1561
Gammaplex <sup>††</sup>	immune globulin <sup>††</sup>	J1557
Gamunex-C <sup>‡</sup>	immune globulin <sup>‡</sup>	J1561
Gattex <sup>‡</sup>	teduglutide <sup>‡</sup>	C9399, J3490
Gazyva	obinutuzumab	J9301
Gel-One <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7326
Gelsyn-3 <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7328

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Genvisc 850 <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7320
Givlaari	givosiran	J0223
Glassia	alpha 1-proteinase inhibitor	J0257
Granix <sup>††</sup>	tbo-filgrastim <sup>††</sup>	J1447
Growth hormones: Genotropin, Humatrope, Norditropin FlexPro, Nutropin AQ NuSpin, Omnitrope, Saizen, Serostim, Zomacton, Zorbtive ‡	somatropin †	J2941
H.P. Acthar Gel	corticotropin	J0801
Haegarda	c1 esterase inhibitor subcutaneous	J0599
Herceptin <sup>††</sup>	trastuzumab <sup>††</sup>	J9355
Herceptin Hylecta <sup>‡,††</sup>	trastuzumab and hyaluronidase- oysk <sup>‡,††</sup>	J9356
Hercessi IV <sup>*,†,‡</sup>	trastuzumab-strf <sup>*,†,‡</sup>	C9399, J3490, J3590, J9999
Herzuma <sup>††</sup>	trastuzumab-pkrb <sup>††</sup>	Q5113
Hizentra	immune globulin	J1559
Hyalgan <sup>‡,††</sup>	sodium hyaluronate <sup>‡,††</sup>	J7321
Hymovis <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7322
Hyqvia <sup>††</sup>	immune globulin <sup>††</sup>	J1575
iDose TR 75 mcg intracameral implant	travoprost intracameral implant	J7355
Ilaris	canakinumab	J0638
Ilumya <sup>††</sup>	tildrakizumab-asmn <sup>††</sup>	J3245
Iluvien	fluocinolone acetonide	J7313
Imdelltra <sup>*,†,‡</sup>	tarlatamab-dlle <sup>*,†,‡</sup>	C9170, J3490, J3590, J9999
Imfinzi	durvalumab	J9173
Imjudo <sup>*,†</sup>	tremelimumab-actl <sup>*,†</sup>	J9347
Imlygic	talimogene laherparepvec	J9325
Inflectra <sup>††</sup>	infliximab-dyyb <sup>††</sup>	Q5103
infliximab <sup>‡</sup>	infliximab <sup>‡</sup>	J1745

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
Injectafer <sup>††</sup>	ferric carboxymaltose <sup>††</sup>	J1439
Istodax	romidespin	J9319
Ixempra	ixabepilone	J9207
Izervay	avacincaptad pegol intravitreal solution	J2782
Jelmyto <sup>‡</sup>	mitomycin <sup>‡</sup>	J9281
Jemperli	dostarlimab-gxly	J9272
Jevtana	cabazitaxel	J9043
Kadcyla	ado-trastuzumab emtansine	J9354
Kalbitor <sup>††</sup>	ecallantide <sup>††</sup>	J1290
Kanjinti	trastuzumab-anns	Q5117
Kanuma	sebelipase alfa	J2840
Kebilidi <sup>†,*,‡,‡†</sup>	eladocagene exuparvovec-tneq <sup>†,*,‡,‡†</sup>	C9399, J3490, J3590
Keytruda	pembrolizumab	J9271
Khapzory <sup>††</sup>	levoleucovorin <sup>††</sup>	J0642
Kimmtrak	tebentafusp-tebn	J9274
Kisunla <sup>*,†</sup>	donanemab-azbt <sup>*,†</sup>	J0175
Korsuva	difelikefalin	J0879
Krystexxa <sup>††</sup>	pegloticase <sup>††</sup>	J2507
Kymriah <sup>‡†</sup>	tisagenlecleucel <sup>‡†</sup>	Q2042
Kyprolis	carfilzomib	J9047
Lamzede <sup>*,†</sup>	velmanase alfa-tycv <sup>*,†</sup>	J0217
lanreotide <sup>*,†,‡</sup>	lanreotide <sup>*,†,‡</sup>	J1930
lanreotide (Cipla)	lanreotide	J1932
Lantidra <sup>*,‡,‡†</sup>	donislecel-jujn <sup>*,‡,‡†</sup>	C9399, J3490, J3590
Lemtrada <sup>††</sup>	alemtuzumab <sup>††</sup>	J0202
Lenmeldy <sup>†,*,‡,‡†</sup>	atidarsagene autotemcel <sup>†,*,‡,‡†</sup>	C9399, J3490
Leqembi <sup>*,†</sup>	lecanemab-irmb <sup>*,†</sup>	J0174
Leqvio	inclisiran	J1306
Leukine	sargramostim	J2820
levoleucovorin <sup>‡,‡†</sup>	levoleucovorin calcium <sup>‡,‡†</sup>	J0641

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡† Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Libtayo	cemiplimab-rwlc	J9119
Loqtorzi	toripalimab-tpzi	J3263
Lucentis <sup>††</sup>	ranibizumab <sup>††</sup>	J2778
Lumizyme	alglucosidase alfa	J0221
Lunsumio <sup>*,†</sup>	mosunetuzumab-axgb <sup>*,†</sup>	J9350
Lutathera <sup>††</sup>	lutetium Lu 177 dotatate <sup>††</sup>	A9513
Luxturna	voretigene neparvovec-rzyl	J3398
Lyfgenia <sup>††</sup>	lovotibeglogene autotemcel <sup>††</sup>	J3394
Macrilen <sup>‡</sup>	macimorelin <sup>‡</sup>	C9399, J8499
Margenza	margetuximab-cmkb	J9353
Mepsevii	vestronidase alfa-vjvk	J3397
Mircera	methoxy polyethylene glycol - epoetin beta	J0887, J0888
Monjuvi <sup>‡</sup>	tafasitamab-cxix <sup>‡</sup>	J9349
Monoferri <sup>††</sup>	ferric derisomaltose <sup>††</sup>	J1437
Mozobil <sup>‡</sup>	plerixafor <sup>‡</sup>	J2562
Mvasi	bevacizumab-awwb	Q5107
Mylotarg	gemtuzumab ozogamicin	J9203
Myobloc <sup>††</sup>	rimabotulinumtoxinB <sup>††</sup>	J0587
Naglazyme	galsulfase	J1458
Neulasta <sup>‡,††</sup>	pegfilgrastim <sup>‡,††</sup>	J2506
Neulasta Onpro <sup>‡,††</sup>	pegfilgrastim <sup>‡,††</sup>	J2506
Neupogen <sup>††</sup>	filgrastim <sup>††</sup>	J1442
Nexviazyme	avalglucosidase alfa-ngpt	J0219
Ngenla <sup>*,†,‡</sup>	somatrogon-ghla <sup>*,†,‡</sup>	C9399, J3490, J3590
Nivestym	filgrastim-aafi	Q5110
Nplate	romiplostim	J2796
Nucala	mepolizumab	J2182
Nulibry <sup>‡</sup>	fosdenopterin <sup>‡</sup>	C9399, J3490
Nulojix	belatacept	J0485
Nuwiq	simoctocog alfa	J7209
Nypozi <sup>*,†,‡</sup>	filgrastim-txid <sup>*,†,‡</sup>	C9173, J3490, J3590, J9999

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).



<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
Nyvepria <sup>‡,††</sup>	pegfilgrastim-apgf <sup>†,††</sup>	Q5122
Ocrevus <sup>††</sup>	ocrelizumab <sup>††</sup>	J2350
Ocrevus Zunovo <sup>*,†,‡</sup>	ocrelizumab and hyaluronidase-acsq <sup>*,†,‡</sup>	C9399, J3490, J3590
Octagam	immune globulin	J1568
Ogivri	trastuzumab-dkst	Q5114
Ohtuvayre <sup>*,†,‡</sup>	ensifentrine <sup>*,†,‡</sup>	J7699
Omisirge <sup>*,‡,††</sup>	omidubicel-onlv <sup>*,‡,††</sup>	C9399, J3490, J3590
OmvoH IV <sup>‡,††</sup>	mirikizumab-mrkz <sup>‡,††</sup>	J2267
Oncaspar	pegaspargase	J9266
Onivyde <sup>††</sup>	irinotecan liposome injection <sup>††</sup>	J9205
Onpattro	patisiran	J0222
Ontruzant <sup>††</sup>	trastuzumab-dttb <sup>††</sup>	Q5112
Opdivo	nivolumab	J9299
Opdualag intravenous vial <sup>††</sup>	nivolumab and relatlimab-rmbw injection <sup>††</sup>	J9298
Orencia IV <sup>††</sup>	abatacept <sup>††</sup>	J0129
Oxlumo	lumasiran	J0224
Ozurdex	dexamethasone intravitreal implant	J7312
paclitaxel protein-bound <sup>††</sup>	paclitaxel protein-bound <sup>††</sup>	J9258
Padcev <sup>‡</sup>	enfortumab vedotin-ejfv <sup>‡</sup>	J9177
Palyngziq <sup>‡</sup>	pegvaliase-pqpz <sup>‡</sup>	C9399, J3490, J3590
Panzyga <sup>††</sup>	immune globulin <sup>††</sup>	J1576
Parsabiv	etelcalcetide	J0606
Pavblu <sup>*,†,‡</sup>	aflibercept-ayyh <sup>*,†,‡</sup>	C9399, J3490, J3590
Pedmark IV solution <sup>*,†</sup>	sodium thiosulfate <sup>*,†</sup>	J0208
pemetrexed	pemetrexed	J9305
pemetrexed (Accord)	pemetrexed	J9296
pemetrexed (BluePoint Laboratories)	pemetrexed	J9322
pemetrexed (Hospira)	pemetrexed	J9294, J9323

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
pemetrexed (Sandoz)	pemetrexed	J9297
pemetrexed (Teva)	pemetrexed	J9314
Pemfexy	pemetrexed injection	J9304
Pemrydi RTU *	pemetrexed *	J9324
Perjeta	pertuzumab	J9306
Polivy	polatuzumab vedotin-piiq	J9309
Phesgo <sup>‡</sup>	pertuzumab, trastuzumab, and hyaluronidase-zzxf <sup>‡</sup>	J9316
Piasky <sup>*,†,‡</sup>	crovalimab-akkz <sup>*,†,‡</sup>	C9399, J3490, J3590
plerixafor <sup>‡</sup>	plerixafor <sup>‡</sup>	J2562
Pluvicto	lutetium Lu 177 vipivotide tetraxetan	A9607
Portrazza	necitumumab	J9295
Pombiliti	cipaglucoasidase alfa-atga	J1203
Poteligeo	mogamulizumab-kpkc	J9204
pralatrexate IV <sup>*,‡</sup>	pralatrexate <sup>*,‡</sup>	J9307
Prevymis IV <sup>‡</sup>	letermovir <sup>‡</sup>	C9399, J3490
Prialt <sup>††</sup>	ziconotide <sup>††</sup>	J2278
Privigen	immune globulin	J1459
Procrit <sup>‡</sup>	epoetin alfa <sup>‡</sup>	J0885, Q4081
Prolastin-C <sup>‡,††</sup>	alpha 1-proteinase inhibitor <sup>‡,††</sup>	J0256
Prolia <sup>‡,††</sup>	denosumab <sup>‡,††</sup>	J0897
Provenge	sipuleucel-T	Q2043
Qalsody	tofersen	J1304
Qutenza <sup>††</sup>	capsaicin/skin cleanser <sup>††</sup>	J7336
Radicava	edaravone	J1301
Reblozyl <sup>‡</sup>	luspatercept-aamt <sup>‡</sup>	J0896
Releuko <sup>††</sup>	filgrastim-ayow injection <sup>††</sup>	Q5125
Remicade	infliximab	J1745
Remodulin <sup>‡,††</sup>	treprostinil (injection) <sup>‡,††</sup>	J3285, J3490
Renflexis <sup>††</sup>	infliximab-abda <sup>††</sup>	Q5104
Retacrit	epoetin alfa-epbx	Q5105, Q5106

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
Rethymic <sup>*, ‡, ††</sup>	allogeneic processed thymus tissue-agdc <sup>*, ‡, ††</sup>	C9399, J3490, J3590
Retisert	fluocinolone acetonide	J7311
Revatio <sup>‡, ††</sup>	sildenafil citrate (injection) <sup>‡, ††</sup>	J3490, J8499
Riabni	rituximab-arrx <sup>††</sup>	Q5123
Rituxan <sup>††</sup>	rituximab	J9312
Rituxan Hycela <sup>††</sup>	rituximab/hyaluronidase human <sup>††</sup>	J9311
Roctavian <sup>*, †</sup>	valoctocogene roxaparvovec-rvox <sup>*, †</sup>	J1412
Rolvedon <sup>*, ‡, ††</sup>	eflapegrastim-xnst <sup>*, ‡, ††</sup>	J1449
romidepsin	romidepsin	J9318
Ruconest <sup>††</sup>	c1 esterase inhibitor <sup>††</sup>	J0596
Ruxience <sup>‡</sup>	rituximab-pvvr <sup>‡</sup>	Q5119
Rybrevant IV	amivantamab-vmjw	J9061
Rylaze	asparaginase erwinia chrysanthemi (recombinant)-rywn	J9021
Ryplazim	plasminogen, human-tvmh	J2998
Rystiggo <sup>*, ‡, ††</sup>	rozanolixizumab-noli <sup>*, ‡, ††</sup>	J9333
Rytelo <sup>*, ‡, ‡</sup>	imetelstat <sup>*, ‡, ‡</sup>	C9399, J3490
Sajazir <sup>‡</sup>	icatibant <sup>‡</sup>	J1744
Sandostatin LAR <sup>††</sup>	octreotide <sup>††</sup>	J2353
Saphnelo intravenous solution	anifrolumab-fnia	J0491
Sarclisa <sup>‡</sup>	isatuximab-irfc <sup>‡</sup>	J9227
Scenesse <sup>‡</sup>	afamelanotide <sup>‡</sup>	J7352
Signifor LAR <sup>††</sup>	pasireotide <sup>††</sup>	J2502
Simponi ARIA	golimumab	J1602
Sinuva <sup>††</sup>	mometasone furoate <sup>††</sup>	J7402
Skyrizi IV	risankizumab-rzaa	J2327
Skysona <sup>*, ‡, ††</sup>	elivaldogene autotemcel <sup>*, ‡, ††</sup>	C9399, J3490, J3590
sodium hyaluronate <sup>‡, ††</sup>	sodium hyaluronate <sup>‡, ††</sup>	C9399, J3490
sodium thiosulfate (Hope)	sodium thiosulfate	J0209
Sogroya <sup>*, ‡, ‡</sup>	somapacitan-beco <sup>*, ‡, ‡</sup>	C9399, J3490, J3590
Soliris	eculizumab	J1300

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Somatuline Depot ‡	lanreotide ‡	J1930
Spevigo IV	spesolimab-sbzo	J1747
Spinraza	nusinersen	J2326
Spravato	esketamine	S0013, G2082, G2083
Stelara (IV only)	ustekinumab (IV only)	J3358
Stimufend*,†,††	pegfilgrastim-fpgk*,†,††	Q5127
Strensiq‡	asfotase alfa‡	C9399, J3590
Sunlenca*,†	lenacapavir*,†	J1961
Supartz FX‡,††	sodium hyaluronate‡,††	J7321
Sustol††	granisetron††	J1627
Susvimo††	ranibizumab††	J2779
Syfovre	pegcetacoplan	J2781
Synagis	palivizumab	90378
SynoJoynt††	1% sodium hyaluronate††	J7331
Synribo	omacetaxine mepesuccinate	J9262
Synvisc‡,††	hylan G-F 20‡,††	J7325
Synvisc-One‡,††	hylan G-F 20‡,††	J7325
Takhzyro††	lanadelumab-flyo††	J0593
Takhzyro subcutaneous*,†,‡	lanadelumab-flyo*,†,‡	J0593
Talvey	talquetamab-tgvs	J3055
Tecartus‡	brexucabtagene autoeucel‡	Q2053
Tecelra*,†,‡,‡‡	afamitresgene autoleucel*,†,‡,‡‡	C9399, J3490, J9999
Tecentriq	atezolizumab	J9022
Tecentriq Hybreza SQ*,†,‡	atezolizumab and hyaluronidase-tqjs*,†,‡	C9399, J3490, J3590, J9999
Tecvayli*,†	teclistamab-cqyv*,†	J9380
Tegsedil‡	inotersen‡	C9399, J3940
Tepezza‡	teprotumumab-trbw‡	J3241
Tevimbra*,†	tislelizumab-jsgr*,†	J9329
Tezspire	tezepelumab-ekko	J2356
Tezspire subcutaneous pen injector*,†	tezepelumab-ekko*,†	J2356

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Tivdak <sup>††</sup>	tisotumab vedotin-tftv <sup>††</sup>	J9273
Thrombate III	antithrombin III [human]	J7197
Tofidence IV <sup>*,†,††</sup>	tocilizumab-bavi <sup>*,†,††</sup>	Q5133
Trazimera	trastuzumab-qyyp	Q5116
Treanda	bendamustine hydrochloride	J9033
Tremfya IV <sup>*,†,‡</sup>	guselkumab <sup>*,†,‡</sup>	J1628
Triluron <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7332
Triptodur <sup>††</sup>	triptorelin <sup>††</sup>	J3316
Trisenox	arsenic trioxide	J9017
TriVisc <sup>††</sup>	sodium hyaluronate <sup>††</sup>	J7329
Trodelvy <sup>‡</sup>	sacituzumab govitecan-hziy <sup>‡</sup>	J9317
Truxima <sup>††</sup>	rituximab-abbs <sup>††</sup>	Q5115
Tyenne IV <sup>*,†,††</sup>	tocilizumab-aazg <sup>*,†,††</sup>	Q5135
Tysabri <sup>††</sup>	natalizumab <sup>††</sup>	J2323
Tyvaso <sup>††</sup>	treprostinil (inhaled) <sup>††</sup>	J7686
Tziel <sup>*,†</sup>	teplizumab-mzww <sup>*,†</sup>	J9381
Udenyca <sup>‡</sup>	pegfilgrastim-cbqv <sup>‡</sup>	Q5111
Udenyca Autoinjector <sup>*,†,‡</sup>	pegfilgrastim-cbqv <sup>*,†,‡</sup>	Q5111
Udenyca Onbody <sup>*,†,‡</sup>	pegfilgrastim-cbqv <sup>*,†,‡</sup>	Q5111
Ultomiris	ravulizumab-cwvz	J1303
Unituxin	dinutuximab	J1246
Uplizna <sup>‡</sup>	inebilizumab-cdon <sup>‡</sup>	J1823
Uptravi <sup>‡,††</sup>	selexipag <sup>‡,††</sup>	C9399, J3490
Vabysmo <sup>††</sup>	faricimab-svoa injection <sup>††</sup>	J2777
Valstar	valrubicin	J9357
VariZIG	varicella zoster immune globulin	90396
Vectibix	panitumumab	J9303
Vegzelma <sup>*,†,††</sup>	bevacizumab-adcd <sup>*,†,††</sup>	Q5129
Velcade <sup>‡</sup>	bortezomib <sup>‡</sup>	J9041
Veletri <sup>‡,††</sup>	epoprostenol <sup>‡,††</sup>	J1325
Ventavis <sup>††</sup>	iloprost (inhaled) <sup>††</sup>	Q4074, J1749
Veopoz <sup>*,†,‡</sup>	pozelimab-bbfg <sup>*,†,‡</sup>	C9399, J3490, J3590

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

Commercial Medication Preauthorization List		
Access the fax forms to request preauthorization or provide notification		
Brand	Generic	Codes
Viltepso <sup>‡</sup>	viltolarsen <sup>‡</sup>	J1427
Vimizim	elosulfase alfa	J1322
Visco-3 <sup>‡,††</sup>	sodium hyaluronate <sup>‡,††</sup>	J7321
Visudyne <sup>††</sup>	verteporfin <sup>††</sup>	J3396
Vivimusta <sup>*,†</sup>	bendamustine hydrochloride <sup>*,†</sup>	J9056
Vpriv	velaglucerase alfa	J3385
Vyepti <sup>‡,††</sup>	eptinezumab-jjmr <sup>‡,††</sup>	J3032
Vyjuvek <sup>*</sup>	beremagene geperpavec-svdt	J3401
Vyloy <sup>*,†,‡</sup>	zolbetuximab-clzb <sup>*,†,‡</sup>	C9399, J3490, J3590, J9999
Vyondys 53	golodirsen	J1429
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	J9334
Vyvgart intravenous solution	efgartigimod alfa-fcab	J9332
Vyxeos	daunorubicin/cytarabine	J9153
Wainua <sup>*,†,‡</sup>	eplontersen injection <sup>*,†,‡</sup>	C9399, J3490
Wezlana IV <sup>*,†</sup>	ustekinumab-auub <sup>*,†</sup>	Q5138
Xembify	immune globulin	J1558
Xenpozyme	olipudase alfa-rpcp	J0218
Xeomin	incobotulinumtoxin A	J0588
Xgeva <sup>‡,††</sup>	denosumab <sup>‡,††</sup>	J0897
Xipere	triamcinolone acetonide	J3299
Xofigo	radium RA 223 dichloride	A9606
Xolair	omalizumab	J2357
Yervoy	ipilimumab	J9228
Yescarta <sup>‡†</sup>	axicabtagene ciloleucel <sup>‡†</sup>	Q2041
Yondelis	trabectedin	J9352
Yutiq	fluocinolone acetonide intravitreal implant	J7314
Zaltrap	ziv-aflibercept	J9400
Zarxio	filgrastim-sndz	Q5101
Zavesca <sup>‡,††</sup>	miglustat <sup>‡,††</sup>	J8499
Zemaira <sup>‡,††</sup>	alpha 1-proteinase inhibitor <sup>‡,††</sup>	J0256
Zepzelca <sup>‡</sup>	lurbinectedin <sup>‡</sup>	J9223

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).

<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
Zevalin	ibritumomab tiuxetan	A9543
Ziextenzo <sup>††</sup>	pegfilgrastim-bmez <sup>††</sup>	Q5120
Ziihera <sup>*,†,‡</sup>	zanidatamab-hrii <sup>*,†,‡</sup>	C9399, J3490, J3590, J9999
Zilretta <sup>††</sup>	triamcinolone acetonide <sup>††</sup>	J3304
Zirabev <sup>‡</sup>	bevacizumab-bvzr <sup>‡</sup>	Q5118
Zoladex <sup>††</sup>	gosrelin acetate <sup>††</sup>	J9202
Zolgensma <sup>‡</sup>	onasemnogene abeparvovec-xioi <sup>‡</sup>	J3399
Zulresso <sup>‡,††</sup>	brexanolone <sup>‡,††</sup>	J1632
Zynlonta	loncastuximab tesirine-lpyl	J9359
Zynteglo <sup>††</sup>	betibeglogene autotemcel <sup>††</sup>	J3393
Zynyz	retifanlimab-dlwr	J9345
<b>Blood-clotting Factors</b>		
Advate <sup>‡</sup>	antihemophilic factor (recombinant) <sup>‡</sup>	J7192
Adynovate	antihemophilic factor (recombinant), PEGylated	J7207
Afstyla	antihemophilic factor (recombinant) single chain	J7210
Alphanate	antihemophilic factor/von Willebrand factor complex (human)	J7186
AlphaNine SD <sup>‡</sup>	coagulation factor IX (human) <sup>‡</sup>	J7193
Alprolix	coagulation factor IX (recombinant)	J7201
Altuviiiio	efanesoctocog alfa	J7214
BeneFix <sup>‡</sup>	coagulation factor IX (recombinant) <sup>‡</sup>	J7195
Beqvez <sup>*,†,‡</sup>	fidanacogene elaparvovec-dzkt <sup>*,†,‡</sup>	C9172, J3490, J3590, J7199
Coagadex	coagulation factor X (human)	J7175
Corifact	factor XIII concentrate (human)	J7180
Eloctate	antihemophilic factor (recombinant), Fc fusion protein	J7205
Esperoct	antihemophilic factor (recombinant), glycopegylated-exei	J7204

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).



<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
Brand	Generic	Codes
Feiba NF	anti-inhibitor coagulant complex	J7198
Hemgenix <sup>*,†</sup>	etranacogene dezaparvovec-drlb <sup>*,†</sup>	J1411
Hemlibra <sup>††</sup>	emicizumab-kxwh <sup>††</sup>	J7170
Hemofil M <sup>‡</sup>	antihemophilic factor (human) <sup>‡</sup>	J7190
Humate-P	antihemophilic factor/von Willebrand factor complex (human)	J7187
Hympavzi <sup>*,†,‡</sup>	marstacimab-hncq <sup>*,†,‡</sup>	C9399, J3490, J3590, J7199
Idelvion	coagulation factor IX (recombinant)	J7202
Ixinity <sup>‡</sup>	coagulation factor IX (recombinant) <sup>‡</sup>	J7213
Jivi <sup>‡</sup>	antihemophilic factor (recombinant), PEGylated-aucl <sup>‡</sup>	J7208
Koate-DVI <sup>‡</sup>	antihemophilic factor (human) <sup>‡</sup>	J7190
Kogenate FS <sup>‡</sup>	antihemophilic factor (recombinant) <sup>‡</sup>	J7192
Kovaltry	antihemophilic factor (recombinant)	J7211
Monoclate-P <sup>‡</sup>	antihemophilic factor (human) <sup>‡</sup>	J7190
Mononine <sup>‡</sup>	coagulation factor IX (human) <sup>‡</sup>	J7193
NovoEight	turoctocog alfa	J7182
NovoSeven RT	coagulation factor VIIa (recombinant)	J7189
Nuwiq	simoctocog alfa	J7209
Obizur	antihemophilic factor (recombinant), porcine sequence	J7188
Profilnine <sup>‡</sup>	factor IX complex <sup>‡</sup>	J7194
Rebinyn	coagulation factor IX (recombinant), GlycoPEGylated	J7203
Recombinat <sup>‡</sup>	antihemophilic factor (recombinant) <sup>‡</sup>	J7192
Rixubis	coagulation factor IX (recombinant)	J7200
Roctavian <sup>*,†,‡</sup>	valoctocogene roxaparvovec-rvox <sup>*,†,‡</sup>	C9399, J3490, J3590, J7190
SevenFact intravenous solution <sup>‡</sup>	coagulation factor VIIa (recombinant)-jncw <sup>‡</sup>	J7212
Tretten	coagulation factor XIII A-subunit (recombinant)	J7181

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).



<b>Commercial Medication Preauthorization List</b> <b>Access the fax forms to request preauthorization or provide notification</b>		
<b>Brand</b>	<b>Generic</b>	<b>Codes</b>
Vonvendi	von Willebrand factor (recombinant)	J7179
Wilate	von Willebrand factor/coagulation factor VIII complex (human)	J7183
Xyntha <sup>†</sup>	antihemophilic factor (recombinant) ‡	J7185
Xyntha Solofuse <sup>‡</sup>	antihemophilic factor (recombinant) ‡	J7185

\* New preauthorization requirement

† New-to-market drug addition

‡ All shared Healthcare Common Procedure Coding System codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.

†† Step therapy required through a Humana preferred drug as part of preauthorization

‡‡ Preauthorization requests will be reviewed by Humana National Transplant Network and can be submitted by fax to **502-508-9300**, telephone at **866-421-5663** or email to [transplant@Humana.com](mailto:transplant@Humana.com).